← Leaderboards
Matthew Albert Rysavy
University Of Iowa
$826,240
Attributed
$826,240
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $343.2K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$826,240 · 2
By mechanism
UG1$686,378 · 1
F32$139,862 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Iowa
Same institution · by research overlap
- Edward F Bell$5,888,647
- Amy Lynn Conrad$3,656,384
- Chadi A. Calarge$13,950,086
- Ekhard E Ziegler$3,807,508
- Ingrid E. Nygaard$9,909,095
Others in their field
Other Emerging Leaders on “Infant”
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$29,616,650
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$21,941,048
- Robert Wilson Frenck · Cincinnati Childrens Hosp Med Ctr$15,645,835
- Sara Bonamo Demauro · Children'S Hosp Of Philadelphia$11,606,693
- Rajni Samavedam · Booz Allen Hamilton$9,935,296
Research focus
InfantMortalityPublishingPremature BirthScienceMulticenter Neonatal Research NetworkMorbidity - Disease RateInnovationNational Institute Of Child Health And Human DevelopmentNewborn InfantSkillsBirthNeurodevelopmental ImpairmentNeonatologyClinical TrialsCohortImpairmentEconomic EvaluationBronchopulmonary DysplasiaBlack RaceAwardClinical PracticeBiometryAsthma
Grant awards (4)
NICHD Neonatal Research Network (NRN): Clinical Centers (UG1 Clinical Trial Optional$343,189
UG1 · FY2025 · HD · contact PI
NICHD Neonatal Research Network (NRN): Clinical Centers (UG1 Clinical Trial Optional$343,189
UG1 · FY2024 · HD · contact PI
Development and evaluation of a risk-based approach to target vitamin A therapy to prevent bronchopulmonary dysplasia among very low birth weight infants$72,458
F32 · FY2020 · HD · contact PI
Development and evaluation of a risk-based approach to target vitamin A therapy to prevent bronchopulmonary dysplasia among very low birth weight infants$67,404
F32 · FY2019 · HD · contact PI